Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Current Leases (2016 - 2025)

Historic Current Leases for Adma Biologics (ADMA) over the last 14 years, with Q3 2025 value amounting to $1.3 million.

  • Adma Biologics' Current Leases rose 880.13% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 880.13%. This contributed to the annual value of $1.2 million for FY2024, which is 1655.5% up from last year.
  • Latest data reveals that Adma Biologics reported Current Leases of $1.3 million as of Q3 2025, which was up 880.13% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Current Leases ranged from a high of $1.3 million in Q3 2025 and a low of $317910.0 during Q1 2021
  • In the last 5 years, Adma Biologics' Current Leases had a median value of $979536.0 in 2023 and averaged $888314.8.
  • In the last 5 years, Adma Biologics' Current Leases skyrocketed by 10571.95% in 2022 and then plummeted by 131.35% in 2025.
  • Quarter analysis of 5 years shows Adma Biologics' Current Leases stood at $591084.0 in 2021, then surged by 53.11% to $905000.0 in 2022, then grew by 15.47% to $1.0 million in 2023, then increased by 16.56% to $1.2 million in 2024, then grew by 6.57% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $1.1 million for Q2 2025, and $1.2 million during Q1 2025.